Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/25/2026, 12:00:00 AM
Announced positive topline results from a Phase 2 trial in China for UBT251, a triple-agonist drug for type 2 diabetes and obesity, showing significant reductions in blood sugar and body weight.
Korean Translation
제2형 당뇨병 및 비만 치료를 위한 3중 작용제 약물인 UBT251의 중국 2상 임상시험에서 혈당과 체중의 현저한 감소를 보이는 긍정적인 탑라인 결과를 발표함.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release is scheduled; medium importance is estimated based on expected >=5% price impact.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
First quarter 2026 earnings release scheduled for April 30, 2026. Medium importance is estimated based on typical price volatility during earnings announcements, and the release is scheduled.
4/30/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Other
The FDA's Oncologic Drugs Advisory Committee (ODAC) is scheduled to meet on 2026-04-30 to review applications for camizestrant for breast cancer and a label expansion for Truqap in prostate cancer, scheduled.
4/30/2026, 12:00:00 AM